MedTrace Logo

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05188664 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-02-17

No results posted yet for this study

Summary

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LM-302

LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。

DRUG

Toripalimab

Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.

Sponsors & Collaborators

  • LaNova Australia Pty Limited

    lead INDUSTRY

Principal Investigators

  • Vinod Ganju · Peninsula & South Eastern Haematology and Oncology Group

  • Ben Markman · The Alfred

  • Sophia Frentzas · Monash Medical Centre Clayton

  • Sara Wahlroos · Chris O'Brien Lifehouse

  • Jessica Smith · Macquarie University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-10
Primary Completion
2023-11-14
Completion
2023-11-14

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05188664 on ClinicalTrials.gov